Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns)

References

• Alvi MM, Chatterjee P. A prospective analysis of co-processed non-ionic surfactants in enhancing permeability of a model hydrophilic drug. AAPS PharmSciTech, 2014;15(2):339–53.
   PubMed Web of Science ®Google Scholar
• Amore BM, Kalhorn TF, Skiles GL, Hunter AP, Bennett GD, Finnell RH, Nelson SD, Slattery JT. Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicity. Drug Metab Dispos, 1997;25(8):953–61.
   PubMed Web of Science ®Google Scholar
• Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 2007;52(2):333–46.
   PubMed Web of Science ®Google Scholar
• Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: A phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2012;11(7):579–88.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin. Pharmacokinet, 1986;11(3):177–98.
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet, 1999;37(6):485–505.
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet, 1985;10(1):80–90.
   PubMed Web of Science ®Google Scholar
• Eun SH, Eun BL, Lee JS, Hwang YS, Kim KJ, Lee YM, Lee IG, Lee M, Ko TS, Kim JT, et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain Dev, 2012;34(10):818–23.
   PubMed Web of Science ®Google Scholar
• Falcone JA, Salameh TS, Yi X, Cordy BJ, Mortell WG, Kabanov AV, Banks WA. Intranasal administration as a route for drug delivery to the brain: Evidence for a unique pathway for albumin. J Pharmacol Exp Ther, 2014;351(1):54–60.
   PubMed Web of Science ®Google Scholar
• Grzesiak AL, Lang M, Kim K, Matzger AJ. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci, 2003;92(11):2260–71.
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC, Tomson T. Sudden unexpected death in epilepsy. Potential role of antiepileptic drugs. CNS Drugs, 2013;27(2):113–19.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Ito S, Itai S, Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm, 2000;193(2):137–46.
   PubMed Web of Science ®Google Scholar
• Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol, 1992;33:611–15.
   PubMed Web of Science ®Google Scholar
• Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm, 2003;257(1-2):169–80.
   PubMed Web of Science ®Google Scholar
• Li C, Li Y, Gao Y, Wei N, Zhao X, Wang C, Li Y, Xiu X, Cui J. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous? Int J Pharm, 2014;468(1-2):15–25.
   PubMed Web of Science ®Google Scholar
• Lu W, Uetrecht JP. Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab. Dispos, 2008;36(8):1624–36.
   PubMed Web of Science ®Google Scholar
• Mackichan JJ, Zola EM. Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol, 1984;18(4):487–93.
   PubMed Web of Science ®Google Scholar
• Massey CA, Sowers LP, Dlouhy BJ, Richerson GB. Mechanisms of sudden unexpected death in epilepsy: The pathway to prevention. Nat Rev Neurol, 2014;10(5):271–82.
   PubMed Web of Science ®Google Scholar
• Neumann E, Frei E, Funk D, Becker MD, Schrenk HH, Muller-Ladner U, Fiehn C. Native albumin for targeted drug delivery. Expert Opin Drug Deliv, 2010;7(8):15–925.
   Web of Science ®Google Scholar
• Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol, 1992;43(8):1675–82.
   PubMed Web of Science ®Google Scholar
• Salar S, Maslarova A, Lippmann K, Nichtweiss J, Weissberg I, Sheintuch L, Kunz WS, Shorer Z, Friedman A, Heinemann U. Blood-brain barrier dysfunction can contribute to pharmacoresistance of seizures. Epilepsia, 2014;55(8):1255–63.
   PubMed Web of Science ®Google Scholar
• Serralheiro A, Alves G, Fortuna A, Falcão A. Intranasal administration of carbamazepine to mice: A direct delivery pathway for brain targeting. Eur J Pharm Sci, 2014;60:32–9.
   PubMed Web of Science ®Google Scholar
• Shear NH, Spielberg SP, Cannon M, Miller M. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest, 1988;82:1826–32.
   PubMed Web of Science ®Google Scholar
• Young WW, Suryanarayanan R. Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions. J Pharm Sci, 1991;80(5):496–500.
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Büchel C, von Briesen H, Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release, 2009;137(1):78–86.
   PubMed Web of Science ®Google Scholar